Forbes2y
Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita
Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar, Amjevita (adalimumab-atto), at two different list prices: $3,288 and $1,557 per 40 mg pen ...
pharmaphorum8y
Amjevita, first Humira biosimilar approved – but no launch yet
The news came on Friday of the approval of Amjevita, Amgen’s copy of adalimumab, and only the fourth biosimilar to be approved in the US. The FDA has approved it across six different indications ...
Forbes1y
As First Therapeutically Interchangeable Humira-Referenced Biosimilar, Cyltezo Has A Marketing Advantage In U.S.
As such, Cyltezo may gain a distinct marketing advantage over other Humira-referenced biosimilars, such as Amjevita and soon to launch Yusimry. This month, five more Humira biosimilars are ...